Société | France


Onglets principaux

A propos de votre organisation

Eukarÿs is deep-tech Biotech Company of the Genopole of Evry (France). We have developped a proprietary core technology with two main applications, which explains our mixed business model.

One a one hand we develop a radically innovative non-viral therapeutic approach named synthetic gene therapy, which can be used to treat most human diseases while initially focusing on the treatment of liver diseases and cancers. Synthetic gene therapy is designed as safe, non-integrative, well tolerated, self-vectorized, produced at an acceptable cost. Proof of concept of efficacy and tolerability has been obtained for our first therapy.

On the other hand, Eukarÿs also develops high performance bioproduction systems for biologics, including recombinant proteins, viruses and vaccines, and this activity should lead to the creation of an independent subsidiary maturing in 2024.

Finally, our goal is to demonstrate the effectiveness of the synthetic gene therapy in clinical studies, then to conclude a co-development agreement with Pharma in 2024. To achieve this goal and the next critical steps, our financing needs are estimated at between €18M, with current fundraising round of €300,000.


Réseau (0)

Il n'y a pas encore d'organisations dans le réseau.

Activité récente

Vous n'êtes pas connecté(e)

Un certain nombre de contenus vous sont cachés et vous ne bénéficiez pas des fonctionnalités de mises en relation.

Log in or register pour accéder à l’intégralité des contenus et fonctionnalités d’EuroQuity : l’inscription est rapide et gratuite !